GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » Additional Paid-In Capital

ALUR (Allurion Technologies) Additional Paid-In Capital : $157.84 Mil(As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies Additional Paid-In Capital?


Allurion Technologies's quarterly additional paid-in capital increased from Sep. 2024 ($150.69 Mil) to Dec. 2024 ($152.60 Mil) and increased from Dec. 2024 ($152.60 Mil) to Mar. 2025 ($157.84 Mil).

Allurion Technologies's annual additional paid-in capital increased from Dec. 2022 ($99.88 Mil) to Dec. 2023 ($143.01 Mil) and increased from Dec. 2023 ($143.01 Mil) to Dec. 2024 ($152.60 Mil).


Allurion Technologies Additional Paid-In Capital Historical Data

The historical data trend for Allurion Technologies's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies Additional Paid-In Capital Chart

Allurion Technologies Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
2.14 99.88 143.01 152.60

Allurion Technologies Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 143.95 144.77 150.69 152.60 157.84

Allurion Technologies Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Allurion Technologies Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Allurion Technologies Business Description

Traded in Other Exchanges
N/A
Address
11 Huron Drive, Natick, MA, USA, 01760
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Executives
Shantanu Gaur director, officer: Chief Executive Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta director, 10 percent owner 307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth officer: Chief Financial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin director C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson director 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon officer: Chief Commercial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani officer: Chief Medical Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760